drugset / Trial / NCT02699749
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and maximum tolerated dose (MTD) of TAK-931 in participants with advanced nonhematologic tumors.
Timeline
- Start
- 2016-03-24
- Primary completion
- 2019-12-21
- Completion
- 2019-12-21
Publications
- Kuboki Y, Shimizu T, Yonemori K, Kojima T, Kondo S, Koganemaru S, Iwasa S, Harano K, Koyama T, Lu V, Zhou X, Niu H, Yanai T, Garcia-Ribas I, Doi T, Yamamoto N. Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer Res Commun. 2022 Nov 14;2(11):1426-1435. doi: 10.1158/2767-9764.CRC-22-0277. eCollection 2022 Nov.
- Martin JC, Sims JR, Gupta A, Bakin AV, Ohm JE. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. Cancer Res Commun. 2022 Jun;2(6):471-482. doi: 10.1158/2767-9764.crc-22-0130. Epub 2022 Jun 20.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIMUROSERTIB | Small molecule | 20 mg | Oral |
| Subject | SIMUROSERTIB | Small molecule | 30 mg | Oral |
| Subject | SIMUROSERTIB | Small molecule | 50 mg | Oral |
| Subject | SIMUROSERTIB | Small molecule | 60 mg | Oral |
| Subject | SIMUROSERTIB | Small molecule | 100 mg | Oral |